• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform
Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in patients with CKD, including those receiving dialysis, although clinical trials have identified risks associated with ESA use. We evaluated the effects of changes in dialysis payment policies and product labeling instituted in 2011 on mortality and major cardiovascular events across the United States dialysis population in an open cohort study of patients on dialysis from January 1, 2005, through December 31, 2012, with Medicare as primary payer. We compared observed rates of death and major cardiovascular events in 2011 and 2012 with expected ra...
Source: Journal of the American Society of Nephrology : JASN - September 29, 2016 Category: Urology & Nephrology Authors: Chertow, G. M., Liu, J., Monda, K. L., Gilbertson, D. T., Brookhart, M. A., Beaubrun, A. C., Winkelmayer, W. C., Pollock, A., Herzog, C. A., Ashfaq, A., Sturmer, T., Rothman, K. J., Bradbury, B. D., Collins, A. J. Tags: Clinical Epidemiology Source Type: research

Contrasting Cholesterol Management Guidelines for Adults with CKD
In conclusion, these guidelines show high concordance for statin treatment for adults with CKD.
Source: Journal of the American Society of Nephrology : JASN - April 30, 2015 Category: Urology & Nephrology Authors: Colantonio, L. D., Baber, U., Banach, M., Tanner, R. M., Warnock, D. G., Gutierrez, O. M., Safford, M. M., Wanner, C., Howard, G., Muntner, P. Tags: Clinical Epidemiology Source Type: research

HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients
High concentrations of HDL cholesterol are considered to indicate efficient reverse cholesterol transport and to protect from atherosclerosis. However, HDL has been suggested to be dysfunctional in ESRD. Hence, our main objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis patients with diabetes. Moreover, we investigated the associations between the major protein components of HDL (apoA1, apoA2, and apoC3) and end points. We performed an exploratory, post hoc analysis with 1255 participants (677 men and 578 women) of the German Diabetes Dialysis study. The mean age was 66.3 yea...
Source: Journal of the American Society of Nephrology : JASN - January 30, 2015 Category: Urology & Nephrology Authors: Silbernagel, G., Genser, B., Drechsler, C., Scharnagl, H., Grammer, T. B., Stojakovic, T., Krane, V., Ritz, E., Wanner, C., Marz, W. Tags: Clinical Research Source Type: research

HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients
In conclusion, HDL cholesterol efflux capacity is not a prognostic cardiovascular risk marker in this cohort of patients with diabetes on hemodialysis.
Source: Journal of the American Society of Nephrology : JASN - February 27, 2017 Category: Urology & Nephrology Authors: Kopecky, C., Ebtehaj, S., Genser, B., Drechsler, C., Krane, V., Antlanger, M., Kovarik, J. J., Kaltenecker, C. C., Parvizi, M., Wanner, C., Weichhart, T., Säemann, M. D., Tietge, U. J. F. Tags: Brief Communications Source Type: research

Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis
In conclusion, in this randomized, crossover study, there was no significant difference in the cardiovascular response to HDF or HD with cooled dialysate as assessed with intradialytic MRI.
Source: Journal of the American Society of Nephrology : JASN - March 31, 2017 Category: Urology & Nephrology Authors: Buchanan, C., Mohammed, A., Cox, E., Köhler, K., Canaud, B., Taal, M. W., Selby, N. M., Francis, S., McIntyre, C. W. Tags: Clinical Research Source Type: research

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hou...
Source: Journal of the American Society of Nephrology : JASN - June 30, 2017 Category: Urology & Nephrology Authors: Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., Lipman, M. L. Tags: Clinical Research Source Type: research

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis
Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.
Source: Journal of the American Society of Nephrology : JASN - June 29, 2018 Category: Urology & Nephrology Authors: Marthi, A., Donovan, K., Haynes, R., Wheeler, D. C., Baigent, C., Rooney, C. M., Landray, M. J., Moe, S. M., Yang, J., Holland, L., di Giuseppe, R., Bouma-de Krijger, A., Mihaylova, B., Herrington, W. G. Tags: Meta-Analysis Source Type: research